Cytokinetics Inc (CYTK)

전일 마감가:

$64.80

열려 있는:

$65

하루 거래량:

635.98K

시가총액:

$6.83B

수익:

$7.53M

순이익/손실:

$-526.24M

주가수익비율:

-11.84

EPS:

-5.52

순현금흐름:

$-415.75M

1주 성능:

-3.27%

1개월 성능:

-8.17%

6개월 성능:

+101.60%

1년 성능:

+75.93%

1일 변동 폭

$64.50

$66.12

52주 변동 폭

$25.98

$110.25

Cytokinetics Inc Stock (CYTK) Company Profile

명칭

Cytokinetics Inc

부문

Healthcare (1191)

산업

Biotechnology (688)

전화

650-624-3000

주소

280 East Grand Avenue, South San Francisco, CA

직원

137

트위터

@Cytokinetics

다음 수익 날짜

2024-05-15

최신 SEC 제출 서류

CYTK's Discussions on Twitter

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-01-24	다운그레이드	UBS	Buy → Neutral
2024-01-05	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2023-11-09	개시	Goldman	Buy
2023-11-07	개시	B. Riley Securities	Buy
2023-08-15	개시	SVB Securities	Outperform
2023-02-17	개시	BofA Securities	Neutral
2022-12-23	재확인	Needham	Buy
2022-12-20	개시	Truist	Buy
2022-10-11	개시	UBS	Buy
2022-01-28	개시	Goldman	Buy
2021-12-22	개시	Oppenheimer	Outperform
2021-12-10	개시	JP Morgan	Overweight
2021-10-07	개시	Jefferies	Buy
2021-03-12	개시	Wolfe Research	Outperform
2021-02-18	개시	Barclays	Overweight
2021-01-20	재확인	H.C. Wainwright	Buy
2020-10-29	개시	Goldman	Neutral
2020-07-10	개시	Raymond James	Strong Buy
2020-05-05	개시	Mizuho	Buy
2020-04-09	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2018-09-21	개시	Cantor Fitzgerald	Overweight
2018-09-10	재개	Morgan Stanley	Equal-Weight
2017-11-22	재확인	Morgan Stanley	Overweight
2017-11-22	다운그레이드	Needham	Strong Buy → Buy
2017-11-21	재확인	H.C. Wainwright	Buy
2017-07-31	개시	Morgan Stanley	Overweight
2017-03-08	개시	Rodman & Renshaw	Buy
2017-02-06	업그레이드	Needham	Buy → Strong Buy
2016-12-16	개시	Cantor Fitzgerald	Overweight
2016-07-28	재확인	Needham	Buy
2015-11-10	재확인	FBR Capital	Outperform
2015-11-09	재확인	ROTH Capital	Buy
2015-07-24	재확인	MLV & Co	Buy
2014-12-31	재확인	ROTH Capital	Buy
2014-11-04	업그레이드	MLV & Co	Hold → Buy
2014-04-28	재확인	Needham	Buy

모두보기

Cytokinetics Inc 주식(CYTK)의 최신 뉴스

Cytokinetics to Announce First Quarter Results on May 8, 2024

GlobeNewswire Inc.

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

GlobeNewswire Inc.

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

GlobeNewswire Inc.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

GlobeNewswire Inc.

Cytokinetics Inc (CYTK) 재무 분석

Cytokinetics Inc (CYTK) 매출 2024

Cytokinetics Inc (CYTK) 순이익 2024

Cytokinetics Inc (CYTK) 현금흐름 2024

Cytokinetics Inc (CYTK) 주당 순이익 2024

Cytokinetics Inc 주식 (CYTK) 내부자 거래